Cancer is a disorder brought upon by the accumulation of specific mutations in the cancerous cells. Our understanding of the disease, and potentially its diagnosis and therapeutic treatment, is enhanced by defining the genetic lesions that cause it. We are applying several new techniques to the discovery of new somatic genetic abnormalities in breast cancer: Representational difference analysis (RDA), a method that discovers probes for altered genomic DNA; high complexity representations (HCR), a method that facilitates the genomic analysis of minute, archived or fresh tumor specimens, and Rapid Isolation of cDNA by Hybridization (RICH), a method for rapid transcriptional mapping of large genomic regions. RDA is a DNA subtraction methodology that finds sequences present in one DNA population, the tester, that is absent or reduced in a second, the driver. RDA has been used to discover sequences lost or amplified in the genomic DNA of the cancerous cells. Genetic loss and gene amplification are hallmarks of tumor suppressor genes and oncogenes, respectively. We have been applying RDA to the discovery of sequences amplified in breast cancer. Over a dozen loci undergoing amplification in breast cancer have been identified. The transcriptional mapping of genomic regions. Additionally, HCR will facilitate the genetic analysis of minute samples of tumor biopsies, such as those produced by the InterSPORE DCIS Project. We expect that the continued execution of out stated plan will accomplish our stated goal, the identification of oncogenes that are commonly involved in breast cancer. This project will interface with other ongoing projects in our laboratory that aim to understand the function of the genes we discover.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA068425-05
Application #
6203334
Study Section
Project Start
1999-09-24
Project End
2001-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Navin, Nicholas E; Hicks, James (2010) Tracing the tumor lineage. Mol Oncol 4:267-83
Ueda, Yukiko; Su, Yingjun; Richmond, Ann (2007) CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells. Melanoma Res 17:91-103
Solit, David B; Scher, Howard I; Rosen, Neal (2003) Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30:709-16
Mu, David; Chen, Liyun; Zhang, Xiping et al. (2003) Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell 3:297-302
Solit, David B; Basso, Andrea D; Olshen, Adam B et al. (2003) Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 63:2139-44
Hamaguchi, Masaaki; Meth, Jennifer L; von Klitzing, Christine et al. (2002) DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci U S A 99:13647-52
Munster, Pamela N; Marchion, Douglas C; Basso, Andrea D et al. (2002) Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. Cancer Res 62:3132-7
Subbaramaiah, Kotha; Norton, Larry; Gerald, William et al. (2002) Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277:18649-57
Basso, Andrea D; Solit, David B; Munster, Pamela N et al. (2002) Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21:1159-66
Solit, David B; Zheng, Fuzhong F; Drobnjak, Maria et al. (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986-93

Showing the most recent 10 out of 51 publications